Pediatric Mixed-Phenotype Acute Leukemia: What’s New?
| dc.contributor.author | Batra, Sandeep | |
| dc.contributor.author | Ross, Anthony John | |
| dc.contributor.department | Pediatrics, School of Medicine | en_US |
| dc.date.accessioned | 2023-03-07T18:59:43Z | |
| dc.date.available | 2023-03-07T18:59:43Z | |
| dc.date.issued | 2021-09-16 | |
| dc.description.abstract | Mixed-phenotype acute leukemias (MPAL) are rare in children and often lack consensus on optimal management. This review examines the current controversies and emerging paradigms in the management of pediatric MPAL. We examine risk stratification, outcomes of recent retrospective and prospective collaborative trials, and the role of transplantation and precision genomics, and outline emerging targets and concepts in this rare entity. | en_US |
| dc.eprint.version | Final published version | en_US |
| dc.identifier.citation | Batra S, Ross AJ. Pediatric Mixed-Phenotype Acute Leukemia: What's New?. Cancers (Basel). 2021;13(18):4658. Published 2021 Sep 16. doi:10.3390/cancers13184658 | en_US |
| dc.identifier.uri | https://hdl.handle.net/1805/31699 | |
| dc.language.iso | en_US | en_US |
| dc.publisher | MDPI | en_US |
| dc.relation.isversionof | 10.3390/cancers13184658 | en_US |
| dc.relation.journal | Cancers | en_US |
| dc.rights | Attribution 4.0 International | * |
| dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | * |
| dc.source | PMC | en_US |
| dc.subject | Lineage switch | en_US |
| dc.subject | Minimal residual disease | en_US |
| dc.subject | Mixed-phenotype acute leukemia | en_US |
| dc.subject | Treatment | en_US |
| dc.title | Pediatric Mixed-Phenotype Acute Leukemia: What’s New? | en_US |
| dc.type | Article | en_US |